Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) gapped up prior to trading on Tuesday after HC Wainwright raised their price target on the stock from $48.00 to $65.00. The stock had previously closed at $22.91, but opened at $27.60. HC Wainwright currently has a buy rating on the stock. Pacira BioSciences shares last traded at $26.70, with a volume of 623,434 shares.
Several other equities research analysts have also recently commented on the stock. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC raised their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $26.67.
Get Our Latest Stock Analysis on PCRX
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC lifted its stake in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the last quarter. Ancora Advisors LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $26,000. Caitlin John LLC increased its stake in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the period. 99.73% of the stock is owned by institutional investors.
Pacira BioSciences Trading Up 3.7 %
The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market capitalization of $1.14 billion, a P/E ratio of -12.10 and a beta of 0.71. The company has a 50-day simple moving average of $24.74 and a 200 day simple moving average of $20.81.
About Pacira BioSciences
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Read More
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
